Anti-clotting drug rivaroxaban wins FDA panel's support

03/19/2009 | NYTimes.com

A panel of FDA advisers endorsed the approval of rivaroxaban, an anti-coagulant by Johnson & Johnson and Bayer Healthcare Pharmaceuticals, as a preventive treatment for deep-vein thrombosis and pulmonary embolism in patients undergoing total knee- or hip-replacement surgery. The product could become an alternative to blockbuster drug warfarin if it gains final FDA clearance.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA